Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1992 Jul;85(7):407–411.

Recombinant natural anticoagulants: a review.

P L Harper 1, J M Hermans 1, R W Carrell 1
PMCID: PMC1293549  PMID: 1629851

Full text

PDF
407

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bevilacqua M. P., Pober J. S., Majeau G. R., Cotran R. S., Gimbrone M. A., Jr Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984 Aug 1;160(2):618–623. doi: 10.1084/jem.160.2.618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bick R. L. Disseminated intravascular coagulation and related syndromes: a clinical review. Semin Thromb Hemost. 1988 Oct;14(4):299–338. doi: 10.1055/s-2007-1002793. [DOI] [PubMed] [Google Scholar]
  3. Blauhut B., Necek S., Vinazzer H., Bergmann H. Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res. 1982 Aug 1;27(3):271–278. doi: 10.1016/0049-3848(82)90074-3. [DOI] [PubMed] [Google Scholar]
  4. Cerami A., Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today. 1988 Jan;9(1):28–31. doi: 10.1016/0167-5699(88)91353-9. [DOI] [PubMed] [Google Scholar]
  5. Courtney M., Jallat S., Tessier L. H., Benavente A., Crystal R. G., Lecocq J. P. Synthesis in E. coli of alpha 1-antitrypsin variants of therapeutic potential for emphysema and thrombosis. Nature. 1985 Jan 10;313(5998):149–151. doi: 10.1038/313149a0. [DOI] [PubMed] [Google Scholar]
  6. Emerson T. E., Jr, Fournel M. A., Leach W. J., Redens T. B. Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat. Circ Shock. 1987;21(1):1–13. [PubMed] [Google Scholar]
  7. Gimbrone M. A., Jr, Buchanan M. R. Interactions of platelets and leukocytes with vascular endothelium: in vitro studies. Ann N Y Acad Sci. 1982;401:171–183. doi: 10.1111/j.1749-6632.1982.tb25716.x. [DOI] [PubMed] [Google Scholar]
  8. Harlan J. M., Harker L. A., Reidy M. A., Gajdusek C. M., Schwartz S. M., Striker G. E. Lipopolysaccharide-mediated bovine endothelial cell injury in vitro. Lab Invest. 1983 Mar;48(3):269–274. [PubMed] [Google Scholar]
  9. Harlan J. M., Harker L. A., Striker G. E., Weaver L. J. Effects of lipopolysaccharide on human endothelial cells in culture. Thromb Res. 1983 Jan 1;29(1):15–26. doi: 10.1016/0049-3848(83)90121-4. [DOI] [PubMed] [Google Scholar]
  10. Harlan J. M., Killen P. D., Harker L. A., Striker G. E., Wright D. G. Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest. 1981 Dec;68(6):1394–1403. doi: 10.1172/JCI110390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Harper P. L., Luddington R. J., Daly M., Bruce D., Williamson D., Edgar P. F., Perry D. J., Carrell R. W. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol. 1991 Mar;77(3):360–364. doi: 10.1111/j.1365-2141.1991.tb08584.x. [DOI] [PubMed] [Google Scholar]
  12. Harper P. L., Williamson L., Park G., Smith J. K., Carrell R. W. A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfus Med. 1991 Jun;1(2):121–128. doi: 10.1111/j.1365-3148.1991.tb00020.x. [DOI] [PubMed] [Google Scholar]
  13. Ichinose A., Fujikawa K., Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem. 1986 Mar 15;261(8):3486–3489. [PubMed] [Google Scholar]
  14. Madison E. L., Goldsmith E. J., Gerard R. D., Gething M. J., Sambrook J. F. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature. 1989 Jun 29;339(6227):721–724. doi: 10.1038/339721a0. [DOI] [PubMed] [Google Scholar]
  15. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Owen M. C., Brennan S. O., Lewis J. H., Carrell R. W. Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med. 1983 Sep 22;309(12):694–698. doi: 10.1056/NEJM198309223091203. [DOI] [PubMed] [Google Scholar]
  17. Redens T. B., Leach W. J., Bogdanoff D. A., Emerson T. E., Jr Synergistic protection from lung damage by combining antithrombin-III and alpha 1-proteinase inhibitor in the E. coli endotoxemic sheep pulmonary dysfunction model. Circ Shock. 1988 Sep;26(1):15–26. [PubMed] [Google Scholar]
  18. Scott C. F., Carrell R. W., Glaser C. B., Kueppers F., Lewis J. H., Colman R. W. Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. J Clin Invest. 1986 Feb;77(2):631–634. doi: 10.1172/JCI112346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Taylor F. B., Jr, Emerson T. E., Jr, Jordan R., Chang A. K., Blick K. E. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock. 1988 Nov;26(3):227–235. [PubMed] [Google Scholar]
  20. Triantaphyllopoulos D. C., Cho M. S. Effect of injection of C1 inactivator on the platelet count and blood coagulation in rabbits infused with endotoxin. Thromb Haemost. 1986 Apr 30;55(2):293–293. [PubMed] [Google Scholar]
  21. Walsh P. N., Griffin J. H. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood. 1981 Jan;57(1):106–118. [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES